By Justin Petrone

NanoInk is developing assays that can be used to profile proteins relevant to angiogenesis, Alzheimer's disease, and drug-toxicity monitoring in rodents, BioArray News has learned.

The new products would follow the February launch of a human inflammation cytokine profiling assay, and are part of NanoInk's effort to broaden its business beyond selling instruments and contract research services, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.